Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372086
Status:
COMPLETED
Last Update Posted:
2006-09-06
First Post:
2006-09-03
Brief Title:
Rosiglitazone and Insulin in T1DM Adolescents
Sponsor:
The University of New South Wales
Organization:
The University of New South Wales
Study Overview
Official Title:
The Addition of Rosiglitazone to Insulin in Adolescents With Type 1 Diabetes and Poor Glycaemic Control a Randomized Placebo Controlled Trial
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Type 1 Diabetes is the most common life-long disorder with onset in childhood Patients need insulin injections blood sugar monitoring several times each day and adhere to a strict diet Adequate control of blood glucose is essential to prevent long term kidney and eye complications that result in kidney failure and blindness Adolescence is a time when diabetes is difficult to control due in part to high growth hormone levels causing insulin resistance a state where the body does not respond as strongly to insulin This study will test whether treatment with rosiglitazone an oral medication used frequently in type 2 diabetes will reduce the insulin resistance of adolescence and improve the control of type 1 diabetes during puberty
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| JHH ethics 040211304 | None | None | None |
| CHW ethics 2003037 | None | None | None |